{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:17:08Z","timestamp":1788517028730,"version":"build-2803163510"},"reference-count":98,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Depression remains a leading cause of disability worldwide, yet the predictive validity of many preclinical behavioral assays for antidepressant efficacy remains limited. The differential reinforcement of low-rate behavior (DRL) task has classically been used in rodents to identify antidepressant-like effects, but its utility in non-human primates (NHPs) has not been established. Here, we adapted the DRL task for use in adult male cynomolgus macaques (\n                      <jats:italic toggle=\"yes\">Macaca fascicularis<\/jats:italic>\n                      ) and evaluated its pharmacological sensitivity and translational relevance across 19 compounds spanning multiple drug classes. Antidepressants, including selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, noradrenergic reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and phosphodiesterase-4 (PDE4) inhibitors, generally shifted DRL performance in an antidepressant-like direction, increasing reinforcers earned and inter-response times while decreasing response output. In contrast, benzodiazepine and antipsychotic control compounds did not produce a consistent antidepressant-like profile, whereas stimulant effects were mixed, with nicotine and cocaine also producing overlapping antidepressant-like behavioral effects. Importantly, the primate DRL task identified antidepressant-like effects of PDE4 inhibitors while also capturing emesis, a dose-limiting side effect not observable in rodent models. These findings support the primate DRL task as a translationally relevant platform for screening antidepressant-like efficacy, while also highlighting important design considerations for interpreting pharmacological sensitivity in the NHP setting. By modeling behavioral processes implicated in depression, including response inhibition and temporal regulation, this assay offers a unique opportunity to bridge preclinical and clinical antidepressant development with improved sensitivity to both efficacy and tolerability.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/fbp.0000000000000893","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T21:00:27Z","timestamp":1785790827000},"page":"221-237","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Behavioral and pharmacological validation of the differential reinforcement of low-rate behavior paradigm in non-human primates"],"prefix":"10.1097","volume":"37","author":[{"given":"Casey R.","family":"Vanderlip","sequence":"first","affiliation":[{"name":"Department of Neurobiology and Behavior, University of California, 1400 Biological Science III, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby R.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Systems Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Basile","sequence":"additional","affiliation":[{"name":"Neuroscience and Rare Disease Discovery & Translational Area, Roche Innovation Center, Basel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G.","family":"Wettstein","sequence":"additional","affiliation":[{"name":"Neuroscience and Rare Disease Discovery & Translational Area, Roche Innovation Center, Basel"},{"name":"TriPhase LLC, Territet, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Vivian","sequence":"additional","affiliation":[{"name":"Neuroscience and Rare Disease Discovery & Translational Area, Roche Innovation Center, Basel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Glavis-Bloom","sequence":"additional","affiliation":[{"name":"Systems Neurobiology Laboratory, Salk Institute for Biological Studies, La Jolla, California, USA"},{"name":"Bioscience Division, Center for Neuroscience, SRI International, Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"R1-20260904","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/ijnp\/pyab086","article-title":"Differential potency of venlafaxine, paroxetine, and atomoxetine to inhibit serotonin and norepinephrine reuptake in patients with major depressive disorder.","volume":"25","author":"Aldosary","year":"2022","journal-title":"Int J Neuropsychopharmacol"},{"key":"R2-20260904","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/157015912799362788","article-title":"Sibutramine effects on central mechanisms regulating energy homeostasis.","volume":"10","author":"Ara\u00fajo","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"R3-20260904","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/cap.2007.0066","article-title":"Efficacy and safety of atomoxetine in adolescents with attention-deficit\/hyperactivity disorder and major depression.","volume":"17","author":"Bangs","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R5-20260904","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.biopsych.2018.09.031","article-title":"The impact of stress and major depressive disorder on hippocampal and medial prefrontal cortex morphology.","volume":"85","author":"Belleau","year":"2019","journal-title":"Biol Psychiatry"},{"key":"R6-20260904","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/j.1550-8528.1999.tb00701.x","article-title":"Sibutramine produces dose-related weight loss.","volume":"7","author":"Bray","year":"1999","journal-title":"Obes Res"},{"key":"R7-20260904","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/0091-3057(89)90067-1","article-title":"Effects of corticotropin releasing factor, desipramine and haloperidol on a DRL schedule of reinforcement.","volume":"32","author":"Britton","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"key":"R8-20260904","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/j.1552-4604.1989.tb03376.x","article-title":"The monoamine oxidase inhibitor \u2013 tyramine interaction.","volume":"29","author":"Brown","year":"1989","journal-title":"J Clin Pharmacol"},{"key":"R9-20260904","first-page":"91","article-title":"Phosphodiesterases 4 inhibitors.","volume":"33","author":"Burnouf","year":"1998","journal-title":"Annu Rep Med Chem"},{"key":"R10-20260904","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nlm.2009.08.007","article-title":"Differential involvement of prefrontal cortex, striatum, and hippocampus in DRL performance in mice.","volume":"93","author":"Cho","year":"2010","journal-title":"Neurobiol Learn Mem"},{"key":"R11-20260904","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"R12-20260904","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0028-3908(00)00126-X","article-title":"Combinations of clozapine and phencyclidine: effects on drug discrimination and behavioral inhibition in rats.","volume":"40","author":"Compton","year":"2001","journal-title":"Neuropharmacology"},{"key":"R13-20260904","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s002130050074","article-title":"The serotonin-1A receptor antagonist WAY-100635 modifies fluoxetine\u2019s antidepressant-like profile on the differential reinforcement of low rates 72-s schedule in rats.","volume":"148","author":"Cousins","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"R14-20260904","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0022-3565(24)35265-6","article-title":"Rats selectively bred for responsiveness to 5-hydroxytryptamine(1A) receptor stimulation: differences in differential reinforcement of low rate 72-second performance and response to serotonergic drugs.","volume":"292","author":"Cousins","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"R15-20260904","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0773.1988.tb01842.x","article-title":"Comparison of desipramine, amitriptyline, zimeldine and alaproclate in six animal models used to investigate antidepressant drugs.","volume":"62","author":"Danysz","year":"1988","journal-title":"Pharmacol Toxicol"},{"key":"R16-20260904","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s00213-002-1070-x","article-title":"Differential modulation of efficiency in a food-rewarded \u2018differential reinforcement of low-rate\u2019 72-s schedule in rats by norepinephrine and serotonin reuptake inhibitors.","volume":"162","author":"Dekeyne","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"R17-20260904","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2147\/NDT.S186071","article-title":"Metabonomics reveals peripheral and central short-chain fatty acid and amino acid dysfunction in a naturally occurring depressive model of macaques.","volume":"15","author":"Deng","year":"2019","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R18-20260904","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.neuroimage.2013.08.001","article-title":"Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: implications on treatment of depression and ADHD.","volume":"86","author":"Ding","year":"2014","journal-title":"Neuroimage"},{"key":"R19-20260904","first-page":"39576","article-title":"Clinically relevant drug interactions with monoamine oxidase inhibitors.","volume":"10","author":"Edinoff","year":"2022","journal-title":"Health Psychol Res"},{"key":"R20-20260904","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jad.2008.04.027","article-title":"Antidepressant treatment normalizes hypoactivity in dorsolateral prefrontal cortex during emotional interference processing in major depression.","volume":"112","author":"Fales","year":"2009","journal-title":"J Affect Disord"},{"key":"R22-20260904","first-page":"349","article-title":"Mechanisms of modafinil: a review of current research.","volume":"3","author":"Gerrard","year":"2007","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R23-20260904","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5409\/wjcp.v11.i1.48","article-title":"Impact of stimulant medication on behaviour and executive functions in children with attention-deficit\/hyperactivity disorder.","volume":"11","author":"Hai","year":"2022","journal-title":"World J Clin Pediatr"},{"key":"R25-20260904","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/s41398-018-0316-2","article-title":"Striatal dopamine deficits predict reductions in striatal functional connectivity in major depression: a concurrent 11C-raclopride positron emission tomography and functional magnetic resonance imaging investigation.","volume":"8","author":"Hamilton","year":"2018","journal-title":"Transl Psychiatry"},{"key":"R26-20260904","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/BF02245258","article-title":"Flesinoxan shows antidepressant activity in a DRL 72-s screen.","volume":"107","author":"van Hest","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"R27-20260904","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/00023210-199912010-00006","article-title":"Reboxetine.","volume":"12","author":"Holm","year":"1999","journal-title":"CNS Drugs"},{"key":"R28-20260904","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.npp.1300828","article-title":"Olanzapine-induced suppression of cocaine self-administration in rhesus monkeys.","volume":"31","author":"Howell","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"R29-20260904","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3389\/fnbeh.2019.00258","article-title":"Temporal preparation, impulsivity and short-term memory in depression.","volume":"13","author":"Hsu","year":"2019","journal-title":"Front Behav Neurosci"},{"key":"R30-20260904","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF02245181","article-title":"Can the DRL 72s schedule selectively reveal antidepressant drug activity?","volume":"117","author":"Jackson","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"R31-20260904","doi-asserted-by":"crossref","first-page":"e300730","DOI":"10.1136\/bmjment-2023-300730","article-title":"Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis.","volume":"27","author":"Kamp","year":"2024","journal-title":"BMJ Ment Health"},{"key":"R32-20260904","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/npp.2010.27","article-title":"Inhibition of G-protein-activated inwardly rectifying K+ channels by the selective norepinephrine reuptake inhibitors atomoxetine and reboxetine.","volume":"35","author":"Kobayashi","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R33-20260904","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/00498258809041693","article-title":"Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences.","volume":"18","author":"Krause","year":"1988","journal-title":"Xenobiotica"},{"key":"R34-20260904","doi-asserted-by":"crossref","first-page":"644","DOI":"10.15585\/mmwr.mm7224a1","article-title":"National, state-level, and county-level prevalence estimates of adults aged \u226518 years self-reporting a lifetime diagnosis of depression \u2013 United States, 2020.","volume":"72","author":"Lee","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R35-20260904","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40850-025-00242-2","article-title":"Investigation of depression-like phenotypes and their behavioral correlates in cynomolgus monkeys (Macaca fascicularis).","volume":"10","author":"Li","year":"2025","journal-title":"BMC Zool"},{"key":"R36-20260904","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainresbull.2022.04.003","article-title":"Neural basis of operant behaviors maintained on the differential-reinforcement-of-low-rate (DRL) schedule in rodents.","volume":"185","author":"Liao","year":"2022","journal-title":"Brain Res Bull"},{"key":"R37-20260904","doi-asserted-by":"crossref","first-page":"6871089","DOI":"10.1155\/2017\/6871089","article-title":"The role of neural plasticity in depression: from hippocampus to prefrontal cortex.","volume":"2017","author":"Liu","year":"2017","journal-title":"Neural Plast"},{"key":"R38-20260904","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/mp.2014.24","article-title":"Neuropsychological mechanism underlying antidepressant effect: a systematic meta-analysis.","volume":"20","author":"Ma","year":"2015","journal-title":"Mol Psychiatry"},{"key":"R39-20260904","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000111537","article-title":"Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).","volume":"56","author":"Mallinckrodt","year":"2007","journal-title":"Neuropsychobiology"},{"key":"R40-20260904","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/jpet.119.264069","article-title":"Extending the specificity of DRL 72-s behavior for screening antidepressant-like effects of glutamatergic clinically validated anxiolytic or antidepressant drugs in rats.","volume":"374","author":"Marek","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"R41-20260904","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0022-3565(25)21404-5","article-title":"Selective 5-hydroxytryptamine2 antagonists have antidepressant-like effects on differential-reinforcement-of-low-rate 72-second schedule.","volume":"250","author":"Marek","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"R42-20260904","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0091-3057(93)90153-K","article-title":"Effects of caffeine and PD 116,600 on the differential-reinforcement-of-low rate 72-S (DRL 72-S) schedule of reinforcement.","volume":"45","author":"Marek","year":"1993","journal-title":"Pharmacol Biochem Behav"},{"key":"R43-20260904","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1124\/jpet.115.229922","article-title":"The utility of impulsive bias and altered decision making as predictors of drug efficacy and target selection: rethinking behavioral screening for antidepressant drugs.","volume":"356","author":"Marek","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"R44-20260904","first-page":"573","article-title":"Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.","volume":"25","author":"Mattiuz","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"R45-20260904","doi-asserted-by":"crossref","first-page":"12533","DOI":"10.1096\/fj.202001016RR","article-title":"PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.","volume":"34","author":"McDonough","year":"2020","journal-title":"FASEB J"},{"key":"R46-20260904","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0022-3565(25)32228-7","article-title":"The effects of tricyclic antidepressants on performance under a differential-reinforcement-of-low-rates schedule in rats.","volume":"214","author":"McGuire","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"R47-20260904","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-013-3232-4","article-title":"The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.","volume":"229","author":"Mereu","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"R48-20260904","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-3223(02)01671-2","article-title":"Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.","volume":"53","author":"Michelson","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R49-20260904","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1038\/s41380-022-01661-0","article-title":"The serotonin theory of depression: a systematic umbrella review of the evidence.","volume":"28","author":"Moncrieff","year":"2023","journal-title":"Mol Psychiatry"},{"key":"R50-20260904","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/S1092852900028297","article-title":"Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants.","volume":"13","author":"Montgomery","year":"2008","journal-title":"CNS Spectr"},{"key":"R51-20260904","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1037\/pha0000333","article-title":"Effects of chronic treatment with bupropion on self-administration of nicotine + cocaine mixtures in nonhuman primates.","volume":"28","author":"de Moura","year":"2020","journal-title":"Exp Clin Psychopharmacol"},{"key":"R52-20260904","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0893-133X(01)00427-4","article-title":"Effects of cocaine self-administration on striatal dopamine systems in rhesus monkeys: initial and chronic exposure.","volume":"27","author":"Nader","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"R53-20260904","first-page":"214","article-title":"Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.","volume":"18","author":"Nair","year":"1993","journal-title":"J Psychiatry Neurosci"},{"key":"R54-20260904","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jad.2014.03.019","article-title":"Comparing outcomes of adjunctive treatment in depression: aripiprazole versus bupropion.","volume":"162","author":"Nasr","year":"2014","journal-title":"J Affect Disord"},{"key":"R55-20260904","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pnpbp.2007.06.017","article-title":"Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.","volume":"32","author":"Navarra","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R56-20260904","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiology of depression.","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"},{"key":"R57-20260904","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1037\/a0021042","article-title":"Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys.","volume":"18","author":"Newman","year":"2010","journal-title":"Exp Clin Psychopharmacol"},{"key":"R58-20260904","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/S0022-3565(25)10128-6","article-title":"Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate.","volume":"264","author":"O\u2019Donnell","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R59-20260904","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0091-3057(98)00267-6","article-title":"Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases.","volume":"63","author":"O\u2019Donnell","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"R60-20260904","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/BF00428153","article-title":"Effects of monoamine oxidase inhibitors on performance during differential reinforcement of low response rate.","volume":"78","author":"O\u2019Donnell","year":"1982","journal-title":"Psychopharmacology (Berl)"},{"key":"R61-20260904","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0022-3565(25)33434-8","article-title":"Differential-reinforcement-of-low-rate 72-second schedule: selective effects of antidepressant drugs.","volume":"224","author":"O\u2019Donnell","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"R62-20260904","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0022-3565(25)21842-0","article-title":"Altered effects of desipramine on operant performance after 6-hydroxydopamine-induced depletion of brain dopamine or norepinephrine.","volume":"229","author":"O\u2019Donnell","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"R63-20260904","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.tips.2004.01.003","article-title":"Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).","volume":"25","author":"O\u2019Donnell","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"R64-20260904","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neubiorev.2005.03.018","article-title":"Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule.","volume":"29","author":"O\u2019Donnell","year":"2005","journal-title":"Neurosci Biobehav Rev"},{"key":"R65-20260904","first-page":"30S","article-title":"A review of psychostimulants for adults with depression.","volume":"32","author":"Pary","year":"2015","journal-title":"Fed Pract"},{"key":"R66-20260904","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1111\/bph.15193","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research.","volume":"177","author":"Percie du Sert","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"R67-20260904","first-page":"S106","article-title":"Duloxetine in major depressed patients resistant to SSRIs and\/or venlafaxine.","volume":"22","author":"Pitchot","year":"2010","journal-title":"Psychiatr Danub"},{"key":"R68-20260904","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1192\/bjp.164.3.309","article-title":"The social competition hypothesis of depression.","volume":"164","author":"Price","year":"1994","journal-title":"Br J Psychiatry"},{"key":"R69-20260904","doi-asserted-by":"crossref","first-page":"i120","DOI":"10.1093\/ijnp\/pyae059.208","article-title":"Escitalopram vs bupropion as an adjunctive treatment for acute bipolar I depression: a multi-center open lable trial.","volume":"28","author":"Raju Chithra","year":"2025","journal-title":"Int J Neuropsychopharmacol"},{"key":"R70-20260904","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.phrs.2010.04.002","article-title":"Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review.","volume":"62","author":"Repantis","year":"2010","journal-title":"Pharmacol Res"},{"key":"R71-20260904","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1901\/jeab.1991.56-173","article-title":"A quantitative interresponse-time analysis of DRL performance differentiates similar effects of the antidepressant desipramine and the novel anxiolytic gepirone.","volume":"56","author":"Richards","year":"1991","journal-title":"J Exp Anal Behav"},{"key":"R72-20260904","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0022-3565(25)39570-4","article-title":"Fluoxetine prevents the disruptive effects of fenfluramine on differential-reinforcement-of-low-rate 72-second schedule performance.","volume":"267","author":"Richards","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"R73-20260904","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1901\/jeab.1993.60-361","article-title":"DRL interresponse-time distributions: quantification by peak deviation analysis.","volume":"60","author":"Richards","year":"1993","journal-title":"J Exp Anal Behav"},{"key":"R74-20260904","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0028-3908(00)00142-8","article-title":"PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway.","volume":"40","author":"Robichaud","year":"2001","journal-title":"Neuropharmacology"},{"key":"R75-20260904","doi-asserted-by":"crossref","first-page":"554899","DOI":"10.3389\/fpsyt.2020.554899","article-title":"A systematic review of efficacy, safety, and tolerability of duloxetine.","volume":"11","author":"Rodrigues-Amorim","year":"2020","journal-title":"Front Psychiatry"},{"key":"R76-20260904","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1037\/bne0000405","article-title":"Cholinergic modulation of hippocampally mediated attention and perception.","volume":"135","author":"Ruiz","year":"2021","journal-title":"Behav Neurosci"},{"key":"R77-20260904","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00213-007-0999-1","article-title":"Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult Cynomolgus macaques.","volume":"196","author":"Rutten","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"R78-20260904","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000329417","article-title":"Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration.","volume":"88","author":"Sawyer","year":"2011","journal-title":"Pharmacology"},{"key":"R79-20260904","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1001\/jamapsychiatry.2016.1572","article-title":"Age-dependent effects of methylphenidate on the human dopaminergic system in young vs adult patients with attention-deficit\/hyperactivity disorder: a randomized clinical trial.","volume":"73","author":"Schrantee","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"R80-20260904","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0447.2010.01599.x","article-title":"A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.","volume":"123","author":"Schueler","year":"2011","journal-title":"Acta Psychiatr Scand"},{"key":"R81-20260904","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00431684","article-title":"Behavioral screen for antidepressants: the effects of drugs and electroconvulsive shock on performance under a differential-reinforcement-of-low-rate schedule.","volume":"86","author":"Seiden","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"R82-20260904","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopsycho.2004.11.006","article-title":"Social stress-associated depression in adult female cynomolgus monkeys (Macaca fascicularis).","volume":"69","author":"Shively","year":"2005","journal-title":"Biol Psychol"},{"key":"R83-20260904","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s002130051155","article-title":"The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat.","volume":"147","author":"Sokolowski","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R84-20260904","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: the pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants.","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectr"},{"key":"R85-20260904","doi-asserted-by":"crossref","first-page":"11332","DOI":"10.1038\/srep11332","article-title":"Phosphodiesterase-4D knock-down in the prefrontal cortex alleviates chronic unpredictable stress-induced depressive-like behaviors and memory deficits in mice.","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"key":"R86-20260904","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pnpbp.2017.04.008","article-title":"The recent progress in animal models of depression.","volume":"77","author":"Wang","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R87-20260904","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ijnp\/pyaa048","article-title":"The phosphodiesterase-4 inhibitor roflumilast, a potential treatment for the comorbidity of memory loss and depression in Alzheimer\u2019s disease: a preclinical study in APP\/PS1 transgenic mice.","volume":"23","author":"Wang","year":"2020","journal-title":"Int J Neuropsychopharmacol"},{"key":"R88-20260904","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.drugalcdep.2004.03.010","article-title":"Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine.","volume":"75","author":"Wee","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"R89-20260904","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1037\/a0023292","article-title":"Effects of nicotine on attention and inhibitory control in healthy nonsmokers.","volume":"19","author":"Wignall","year":"2011","journal-title":"Exp Clin Psychopharmacol"},{"key":"R90-20260904","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/syn.20565","article-title":"Blood levels and dopamine transporter occupancy of orally administered methylphenidate in juvenile rhesus monkeys measured by high resolution PET.","volume":"62","author":"Wilcox","year":"2008","journal-title":"Synapse"},{"key":"R91-20260904","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ajp.21013","article-title":"Modeling depression in adult female cynomolgus monkeys (Macaca fascicularis).","volume":"74","author":"Willard","year":"2012","journal-title":"Am J Primatol"},{"key":"R92-20260904","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00427414","article-title":"The validity of animal models of depression.","volume":"83","author":"Willner","year":"1984","journal-title":"Psychopharmacology (Berl)"},{"key":"R93-20260904","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/S0006-3223(99)00291-7","article-title":"Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.","volume":"47","author":"Wong","year":"2000","journal-title":"Biol Psychiatry"},{"key":"R94-20260904","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/BF02246544","article-title":"Effects of several benzodiazepines, alone and in combination with flumazenil, in rhesus monkeys trained to discriminate pentobarbital from saline.","volume":"122","author":"Woolverton","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"R95-20260904","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1038\/srep09220","article-title":"Macaques exhibit a naturally-occurring depression similar to humans.","volume":"5","author":"Xu","year":"2015","journal-title":"Sci Rep"},{"key":"R96-20260904","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0161-813X(03)00097-4","article-title":"Clinical pharmacology of MAO inhibitors: safety and future.","volume":"25","author":"Yamada","year":"2004","journal-title":"Neurotoxicology"},{"key":"R97-20260904","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/13880209.2021.1907422","article-title":"The anti-depressant effects of a novel PDE4 inhibitor derived from resveratrol.","volume":"59","author":"Yu","year":"2021","journal-title":"Pharm Biol"},{"key":"R98-20260904","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-2007-1017435","article-title":"Results of a phase II study of the antidepressant effect of rolipram.","volume":"17","author":"Zeller","year":"1984","journal-title":"Pharmacopsychiatry"},{"key":"R99-20260904","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00213-005-0055-y","article-title":"Interaction between the antidepressant-like behavioral effects of beta adrenergic agonists and the cyclic AMP PDE inhibitor rolipram in rats.","volume":"182","author":"Zhang","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R100-20260904","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00213-006-0369-4","article-title":"Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.","volume":"186","author":"Zhang","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R101-20260904","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/jpet.310.991220","article-title":"Bupropion displays both stimulant-like and antidepressant-like profiles in the differential reinforcement of low rate (DRL) 72\u2009sec operant task.","volume":"389","author":"Zhang","year":"2024","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FBP.0000000000000893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:00:32Z","timestamp":1788516032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FBP.0000000000000893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":98,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000893","relation":{},"ISSN":["0955-8810","1473-5849"],"issn-type":[{"value":"0955-8810","type":"print"},{"value":"1473-5849","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"2026-03-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}